These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

661 related articles for article (PubMed ID: 17438410)

  • 1. Oxidation of low-density lipoprotein cholesterol following administration of poloxamer 407 to mice results from an indirect effect.
    Johnston TP; Zhou X
    J Cardiovasc Pharmacol; 2007 Apr; 49(4):246-52. PubMed ID: 17438410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypercholesterolemia is associated with a T helper (Th) 1/Th2 switch of the autoimmune response in atherosclerotic apo E-knockout mice.
    Zhou X; Paulsson G; Stemme S; Hansson GK
    J Clin Invest; 1998 Apr; 101(8):1717-25. PubMed ID: 9541503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poloxamer 407-induced atherosclerosis in mice appears to be due to lipid derangements and not due to its direct effects on endothelial cells and macrophages.
    Johnston TP; Li Y; Jamal AS; Stechschulte DJ; Dileepan KN
    Mediators Inflamm; 2003 Jun; 12(3):147-55. PubMed ID: 12857598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibodies against human oxidized low-density lipoprotein (LDL) as markers for human plasma modified lipoproteins.
    Radulescu L; Stancu C; Antohe F
    Med Sci Monit; 2004 Jul; 10(7):BR207-14. PubMed ID: 15232494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial.
    Fraley AE; Schwartz GG; Olsson AG; Kinlay S; Szarek M; Rifai N; Libby P; Ganz P; Witztum JL; Tsimikas S;
    J Am Coll Cardiol; 2009 Jun; 53(23):2186-96. PubMed ID: 19497447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Presence of autoantibodies against oxidatively modified low-density lipoprotein in essential hypertension: a biochemical signature of an enhanced in vivo low-density lipoprotein oxidation.
    Maggi E; Marchesi E; Ravetta V; Martignoni A; Finardi G; Bellomo G
    J Hypertens; 1995 Jan; 13(1):129-38. PubMed ID: 7759843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein.
    Tsimikas S; Lau HK; Han KR; Shortal B; Miller ER; Segev A; Curtiss LK; Witztum JL; Strauss BH
    Circulation; 2004 Jun; 109(25):3164-70. PubMed ID: 15184281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autoantibodies to malondialdehyde-modified low-density lipoprotein in patients with angiographically confirmed coronary artery disease.
    McDowell A; Young IS; Wisdom GB
    J Pharm Pharmacol; 2002 Dec; 54(12):1651-7. PubMed ID: 12542895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Malondialdehyde-modified low-density lipoproteins as biomarker for atherosclerosis.
    Viigimaa M; Abina J; Zemtsovskaya G; Tikhaze A; Konovalova G; Kumskova E; Lankin V
    Blood Press; 2010 Jun; 19(3):164-8. PubMed ID: 20429692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of oral tolerance to oxidized low-density lipoprotein ameliorates atherosclerosis.
    van Puijvelde GH; Hauer AD; de Vos P; van den Heuvel R; van Herwijnen MJ; van der Zee R; van Eden W; van Berkel TJ; Kuiper J
    Circulation; 2006 Oct; 114(18):1968-76. PubMed ID: 17060383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxidized low-density lipoprotein in children with familial hypercholesterolemia and unaffected siblings: effect of pravastatin.
    Rodenburg J; Vissers MN; Wiegman A; Miller ER; Ridker PM; Witztum JL; Kastelein JJ; Tsimikas S
    J Am Coll Cardiol; 2006 May; 47(9):1803-10. PubMed ID: 16682304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. OxLDL/beta2GPI complexes and autoantibodies in patients with systemic lupus erythematosus, systemic sclerosis, and antiphospholipid syndrome: pathogenic implications for vascular involvement.
    Lopez LR; Simpson DF; Hurley BL; Matsuura E
    Ann N Y Acad Sci; 2005 Jun; 1051():313-22. PubMed ID: 16126973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [LDL oxidation in homozygous familial hypercholesterolemia: effects of selective LDL-apheresis treatment].
    Napoli C; Postiglione A; Scarpato N; Corso G; Ambrosio G; Condorelli M; Mancini M; Chiariello M
    Cardiologia; 1996 May; 41(5):435-9. PubMed ID: 8767632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autoantibodies against oxidized low-density lipoprotein and C-reactive protein are associated with diabetes and myocardial infarction in women.
    Dotevall A; Hulthe J; Rosengren A; Wiklund O; Wilhelmsen L
    Clin Sci (Lond); 2001 Nov; 101(5):523-31. PubMed ID: 11672458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apolipoprotein B-bound lipids as a marker for evaluation of low density lipoprotein oxidation in vivo.
    Tertov VV; Kaplun VV; Dvoryantsev SN; Orekhov AN
    Biochem Biophys Res Commun; 1995 Sep; 214(2):608-13. PubMed ID: 7677772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of poloxamer 407 on the functional properties of HDL in mice.
    Yasuda T; Johnston TP; Shinohara M; Inoue M; Ishida T
    J Pharm Pharmacol; 2012 May; 64(5):677-87. PubMed ID: 22471363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-(apolipoprotein A-1) IgGs are associated with high levels of oxidized low-density lipoprotein in acute coronary syndrome.
    Vuilleumier N; Charbonney E; Fontao L; Alvarez M; Turck N; Sanchez JC; Burkhard PR; Mensi N; Righini M; Reber G; James R; Mach F; Chevrolet JC; Dayer JM; Frostegard J; Roux-Lombard P
    Clin Sci (Lond); 2008 Jul; 115(1):25-33. PubMed ID: 18088236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Electronegative LDL and lipid abnormalities in patients undergoing hemodialysis and peritoneal dialysis.
    Lobo J; Santos F; Grosso D; Lima R; Barreira AL; Leite M; Mafra D; Abdalla DS
    Nephron Clin Pract; 2008; 108(4):c298-304. PubMed ID: 18434752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High circulating autoantibodies against human oxidized low-density lipoprotein are related to stable and lower titers to unstable clinical situation.
    Santos AO; Fonseca FA; Fischer SM; Monteiro CM; Brandão SA; Póvoa RM; Bombig MT; Carvalho AC; Monteiro AM; Ramos E; Gidlund M; Figueiredo Neto AM; Izar MC
    Clin Chim Acta; 2009 Aug; 406(1-2):113-8. PubMed ID: 19523463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of simvastatin on circulating autoantibodies to oxidized LDL antigens: relation with immune stimulation markers.
    Gonçalves I; Cherfan P; Söderberg I; Nordin Fredrikson G; Jonasson L
    Autoimmunity; 2009 Mar; 42(3):203-8. PubMed ID: 19301201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.